Literature DB >> 25299864

The disconnect between a national tuberculosis drug resistance survey and treatment outcomes: a lost opportunity.

E S Click1, J Chirenda2, S Kibias2, H J Menzies1, J E Oeltmann1, C Sentle2, T Muribe3, T D Lere2, R Makombe4, S Bamrah1, B K Moore1, K P Cain1.   

Abstract

We linked results from the Fourth Botswana National Drug Resistance Survey (DRS), 2007-2008, to patient records from the national Electronic Tuberculosis Registry to determine treatment outcomes. Of 915 new patients, 651 (71%) had treatment data available. Completion or cure was achieved for 10/15 (67%, 95%CI 42-85) with isoniazid monoresistance, (6/16, 38%, 95%CI 18-61) with multidrug resistance, while 73% (391/537, 95%CI 69-76) were susceptible to first-line drugs. The analysis was limited because of unavailable treatment records and undocumented outcomes. Prospective analyses following DRSs should be considered to ensure adequate outcome data.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25299864      PMCID: PMC5931357          DOI: 10.5588/ijtld.13.0710

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  6 in total

1.  Initial default from tuberculosis treatment: how often does it happen and what are the reasons?

Authors:  E Botha; S Den Boon; S Verver; R Dunbar; K-A Lawrence; M Bosman; D A Enarson; I Toms; N Beyers
Journal:  Int J Tuberc Lung Dis       Date:  2008-07       Impact factor: 2.373

2.  Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa.

Authors:  Karen R Jacobson; Danie Theron; Thomas C Victor; Elizabeth M Streicher; Robin M Warren; Megan B Murray
Journal:  Clin Infect Dis       Date:  2011-08       Impact factor: 9.079

3.  Increase in anti-tuberculosis drug resistance in Botswana: results from the fourth National Drug Resistance Survey.

Authors:  H J Menzies; G Moalosi; V Anisimova; V Gammino; C Sentle; M A Bachhuber; E Bile; K Radisowa; O Kachuwaire; J Basotli; T Maribe; R Makombe; J Shepherd; B Kim; T Samandari; S El-Halabi; J Chirenda; K P Cain
Journal:  Int J Tuberc Lung Dis       Date:  2014-09       Impact factor: 2.373

4.  Comparison of isoniazid monoresistant tuberculosis with drug-susceptible tuberculosis and multidrug-resistant tuberculosis.

Authors:  L Fox; M R Kramer; I Haim; R Priess; A Metvachuk; D Shitrit
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-03-24       Impact factor: 3.267

5.  Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis.

Authors:  Adithya Cattamanchi; Raymund B Dantes; John Z Metcalfe; Leah G Jarlsberg; Jennifer Grinsdale; L Masae Kawamura; Dennis Osmond; Philip C Hopewell; Payam Nahid
Journal:  Clin Infect Dis       Date:  2009-01-15       Impact factor: 9.079

Review 6.  Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis.

Authors:  Dick Menzies; Andrea Benedetti; Anita Paydar; Sarah Royce; Pai Madhukar; William Burman; Andrew Vernon; Christian Lienhardt
Journal:  PLoS Med       Date:  2009-09       Impact factor: 11.069

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.